David M. Mott, Director at Epizyme, Inc. (EPZM), bought 124,038 shares at $16.03 ($2.0M) on 2020-06-26, disclosed to the SEC on 2020-06-26.
Open-market purchase of $2.0M EPZM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.03 | 62,019 | $994K | 50.0% |
| 2 | $16.03 | 62,019 | $994K | 50.0% |
| Total | $16.03 avg | 124,038 | $2.0M | 100% |
| Filing → |
| ARDX | BUY | 2025-06-11 | $738K | — | Filing → |
| ARDX | BUY | 2025-05-19 | $329K | — | Filing → |
| ARDX | BUY | 2025-05-05 | $3.2M | — | Filing → |